Journal Basic Info
- Impact Factor: 0.285**
- H-Index: 6
- ISSN: 2638-4558
- DOI: 10.25107/2638-4558
Major Scope
- Dermatology and Cosmetology
- Pediatrics
- Diabetology
- Pathology
- Urology Cases
- Cardiology
- Physiotherapy
- Sleep Medicine and Disorders
Abstract
Citation: Clin Case Rep Int. 2019;3(1):1119.DOI: 10.25107/2638-4558.1119
Use of Trimethoprim-Sulfamethoxazole in Patient with G6PD Deficiency for Treating Pneumocystis Jirovecii Pneumonia
Ya-Wen Lu and Tsung-Chia Chen
Department of Pharmacy, Taichung Hospital, Taiwan Department of Internal Medicine, Taichung Hospital, Taiwan
PDF Full Text Case Report | Open Access
Abstract:
Case Report: A fixed dose of Trimethoprim-Sulfamethoxazole (TMP/SMZ) is the treatment of choice for Pneumocystis Jirovecii Pneumonia (PJP) recommended by Infectious Diseases Society of America (IDSA). However, TMP/SMZ has been reported to cause hemolysis when administered to patients with deficiency. PJP might be fatal without receiving treatment. Therefore, there is a dilemma on the use of TMP/SMZ in G6PD deficient patients. Herein, we report a G6PD deficient patient with PJP treated successfully with 21 days of TMP/SMZ without any signs and symptoms of hemolysis. Conclusion: It might be safe for the Southeast Asia population with a history of G6PD deficiency to administer TMP/SMZ under expert surveillance.
Keywords:
Glucose-6-phosphate dehydrogenase deficiency; HIV; Pneumocystis pneumonia; Trimethoprim-sulfamethoxazole
Cite the Article:
Lu Y-W, Chen T-C. Use of Trimethoprim-Sulfamethoxazole in Patient with G6PD Deficiency for Treating Pneumocystis Jirovecii Pneumonia. Clin Case Rep Int. 2019;3:1119.
